A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Acronyms KOSMIC
- 25 Apr 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 25 Apr 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
- 25 Apr 2017 Status changed from recruiting to active, no longer recruiting.